Reglagene is developing an orally administered, low molecular weight tubulin-targeting therapy that effectively penetrates the blood-brain barrier for the treatment of brain cancers. In preclinical studies, this therapy demonstrated an 84% reduction in tumor growth compared to standard treatments, remaining active in the brain without being expelled by efflux pumps.
Funding
$13.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Brain cancers pose a significant therapeutic challenge due to the blood-brain barrier (BBB), which restricts the entry of many drugs into the brain. Current treatments often fail to achieve sufficient drug concentrations in the brain, leading to limited efficacy and tumor recurrence. Efflux pumps in the brain further reduce drug accumulation by actively removing toxins and therapeutic agents.
Solution
Reglagene is developing an orally bioavailable, small-molecule tubulin inhibitor designed to cross the blood-brain barrier and selectively target brain tumors. The therapy is engineered to evade efflux pump mechanisms, ensuring sustained drug concentrations within the brain. Preclinical studies have demonstrated significant tumor growth reduction compared to standard-of-care treatments, suggesting improved efficacy in treating brain cancers. By targeting tubulin, a key component of cell division, the therapy aims to disrupt cancer cell proliferation and induce apoptosis.
Target Audience
The primary target audience includes patients diagnosed with brain cancers, particularly those with tumors that are difficult to treat due to the blood-brain barrier.
Features
- Orally administered, low molecular weight compound for convenient dosing and improved patient compliance
- Designed to passively cross the blood-brain barrier, overcoming a major obstacle in brain cancer treatment
- Exhibits reduced recognition by efflux pumps, enhancing drug retention in the brain
- Tubulin-targeting mechanism of action disrupts cancer cell division
- Demonstrated 84% tumor growth reduction in preclinical studies compared to standard-of-care temozolomide and placebo